CWB005

CWB005 is a preclinical-stage bispecific antibody being developed by Fosun Pharma USA. It specifically targets the erythropoietin receptor (EPO-R). While EPO-R is traditionally associated with erythropoiesis, its expression on certain solid tumors, such as gastric and pancreatic cancers, has been identified as a potential therapeutic target. CWB005 is designed to leverage the bispecific antibody modality to treat these malignancies, although the exact second target or specific mechanism of action (e.g., whether it acts as an antagonist or a T-cell engager) has not been fully disclosed in public pipeline documents. It is currently categorized as a preclinical candidate (PCC).